CELYAD S.A.

Home » CELYAD S.A.

Follow-on

CELYAD S.A.

Biopharmaceutical

We are a clinical-stage biopharmaceutical company focused on the development of chimeric antigen receptor (CAR) T-lymphocytes (T-cells), or CAR-T, cell-based therapies for the treatment of cancer.

Symbol

CYAD

Last Closing Price
$13.29

Shares
2,000,000

Anticipated Date
September 12, 2019

Underwriters
WELLS FARGO SECURITIES, LLC

This offering is no longer available

To view the prospectus for CELYAD S.A., or any offering listed on ClickIPO,
download the ClickIPO app...

or a prospectus can be requested from G. Price at
ClickIPO Securities, LLC 8601 N Scottsdale Rd, Suite 335, Scottsdale, AZ 85253